The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow,Elias Campo,Stefano Pileri,Nancy L. Harris,Harald Stein,Reiner Siebert,Ranjana H. Advani,Michele Ghielmini,Gilles Salles,Andrew D. Zelenetz,Elaine S. Jaffe +10 more
Reads0
Chats0
TLDR
The revision clarifies the diagnosis and management of lesions at the very early stages of lymphomagenesis, refines the diagnostic criteria for some entities, details the expanding genetic/molecular landscape of numerous lymphoid neoplasms and their clinical correlates, and refers to investigations leading to more targeted therapeutic strategies.About:
This article is published in Blood.The article was published on 2016-05-19 and is currently open access. It has received 5321 citations till now.read more
Citations
More filters
Journal ArticleDOI
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.
Martin Hutchings,Rogier Mous,Michael Roost Clausen,Peter Johnson,Kim Linton,Martine E.D. Chamuleau,David John Lewis,Anna Sureda Balari,David Cunningham,Roberto S. Oliveri,Brian Elliott,Dena DeMarco,Ada Azaryan,Christopher Chiu,Tommy Li,Kuo mei Chen,Tahamtan Ahmadi,Pieternella J. Lugtenburg +17 more
TL;DR: In this article, the safety and recommended phase 2 dose of epcoritamab, a novel bispecific antibody that targets CD3 and CD20 and induces T-cell-mediated cytotoxic activity against CD20+ malignant B cells, were established.
Journal ArticleDOI
Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin–specific clinical impact
Daisuke Ennishi,Anja Mottok,Susana Ben-Neriah,Hennady P. Shulha,Pedro Farinha,Fong Chun Chan,Barbara Meissner,Merrill Boyle,Christoffer Hother,Robert Kridel,Daniel Lai,Saeed Saberi,Ali Bashashati,Sohrab P. Shah,Ryan D. Morin,Marco A. Marra,Kerry J. Savage,Laurie H. Sehn,Christian Steidl,Joseph M. Connors,Randy D. Gascoyne,David Scott +21 more
TL;DR: COO subtype-specific biomarkers based on BCL2 genetic alterations can be used to risk-stratify patients with DLBCL treated with immunochemotherapy and identify extremely poor prognostic groups within each COO subtypes in this large, uniformly R-CHOP-treated population-based cohort ofDLBCL.
Journal ArticleDOI
IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial.
Martine Bagot,Pierluigi Porcu,Anne Marie-Cardine,Maxime Battistella,Basem M. William,Maarten H. Vermeer,Sean Whittaker,Federico Rotolo,Caroline Ram-Wolff,Michael S. Khodadoust,Armand Bensussan,Carine Paturel,Cécile Bonnafous,Hélène Sicard,Hatem A. Azim,Youn H. Kim +15 more
TL;DR: IPH4102 is safe and shows encouraging clinical activity in patients with relapsed or refractory cutaneous T-cell lymphoma, particularly those with Sézary syndrome, and if confirmed in future trials, IPH4 102 could become a novel treatment option for these patients.
Journal ArticleDOI
Follicular lymphoma: Nature Reviews. Disease Primers
Antonino Carbone,Sandrine Roulland,Annunziata Gloghini,Anas Younes,Gottfried von Keudell,Armando López-Guillermo,Jude Fitzgibbon +6 more
Journal ArticleDOI
How I treat double-hit lymphoma
TL;DR: The approach to the evaluation and treatment of double-hit lymphoma is reviewed, with an eye toward future clinical trials incorporating rational targeted agents into the therapeutic armamentarium.
References
More filters
Book
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
TL;DR: Thank you very much for reading who classification of tumours of haematopoietic and lymphoid tissues, and maybe you have knowledge that, people have look hundreds of times for their chosen readings like this, but end up in malicious downloads.
Journal ArticleDOI
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications.
TL;DR: The criteria and significance of early or precursor lesions and the identification of certain lymphoid neoplasms largely associated with particular age groups, such as children and the elderly are addressed, and the issue of borderline categories having overlapping features with large B-cell lymphomas is reviewed.
Journal ArticleDOI
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
Xose S. Puente,Magda Pinyol,Víctor Quesada,Laura Conde,Gonzalo R. Ordóñez,Neus Villamor,Geòrgia Escaramís,Pedro Jares,Sílvia Beà,Marcos González-Díaz,Laia Bassaganyas,Tycho Baumann,Manel Juan,Mónica López-Guerra,Dolors Colomer,Jose M. C. Tubio,Cristina López,Alba Navarro,Cristian Tornador,Marta Aymerich,María Rozman,Jesús M. Hernández,Diana A. Puente,José M.P. Freije,Gloria Velasco,Ana Gutiérrez-Fernández,Dolors Costa,Anna Carrió,Sara Guijarro,Anna Enjuanes,Lluis Hernández,Jordi Yagüe,Pilar Nicolás,Carlos M. Romeo-Casabona,Heinz Himmelbauer,Ester Castillo,Juliane C. Dohm,Silvia de Sanjosé,Miguel A. Piris,Enrique de Alava,Jesús F. San Miguel,Romina Royo,Josep Lluís Gelpí,David Torrents,Modesto Orozco,David G. Pisano,Alfonso Valencia,Roderic Guigó,Mònica Bayés,Simon Heath,Marta Gut,Peter Klatt,John Marshall,Keiran Raine,Lucy Stebbings,P. Andrew Futreal,Michael R. Stratton,Peter J. Campbell,Ivo Gut,Armando López-Guillermo,Xavier Estivill,Emili Montserrat,Carlos López-Otín,Elias Campo +63 more
TL;DR: The patterns of somatic mutation, supported by functional and clinical analyses, strongly indicate that the recurrent NOTCH1, MYD88 and XPO1 mutations are oncogenic changes that contribute to the clinical evolution of the disease.
Journal ArticleDOI
MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia
Steven P. Treon,Lian Xu,Guang Yang,Yangsheng Zhou,Xia Liu,Yang Cao,Patricia Sheehy,Robert Manning,Christopher J. Patterson,Christina K. Tripsas,Luca Arcaini,Geraldine S. Pinkus,Scott J. Rodig,Aliyah R. Sohani,Nancy L. Harris,Jason M. Laramie,Donald A Skifter,Stephen E Lincoln,Zachary R. Hunter +18 more
TL;DR: MYD88 L265P is a commonly recurring mutation in patients with Waldenström's macroglobulinemia that can be useful in differentiating WaldenStröm’s macrogalobulinesia and non-IgM LPL from B-cell disorders that have some of the same features.
Related Papers (5)
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
Christine P. Hans,Dennis D. Weisenburger,Timothy C. Greiner,Randy D. Gascoyne,Jan Delabie,German Ott,H. Konrad Muller-Hermelink,Elias Campo,Rita M. Braziel,Elaine S. Jaffe,Zenggang Pan,Pedro Farinha,Lynette M. Smith,Brunangelo Falini,Alison H. Banham,Andreas Rosenwald,Louis M. Staudt,Joseph M. Connors,James O. Armitage,Wing C. Chan +19 more
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Ash A. Alizadeh,Michael B. Eisen,R. Eric Davis,Izidore S. Lossos,Andreas Rosenwald,Jennifer C. Boldrick,Hajeer Sabet,Truc Tran,Xin Yu,John Powell,Liming Yang,Gerald E. Marti,Troy Moore,James I. Hudson,Li-Sheng Lu,David B. Lewis,Robert Tibshirani,Gavin Sherlock,Wing C. Chan,Timothy C. Greiner,Dennis D. Weisenburger,James O. Armitage,Roger A. Warnke,Ronald Levy,Wyndham H. Wilson,M. R. Grever,John C. Byrd,David Botstein,Patrick O. Brown,Louis M. Staudt +29 more